Menu
Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 2
Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
Authors Thomas X
Received 16 November 2011
Accepted for publication 17 January 2012
Published 5 March 2012 Volume 2012:2 Pages 57—76
DOI https://doi.org/10.2147/BLCTT.S15567
Review by Single anonymous peer review
Peer reviewer comments 3
Xavier Thomas
Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d'Hématologie Clinique, Pavillon Marcel Bérard, Bât.1G, Pierre Bénite, France
Abstract: The choice of treatment approach in acute leukemia depends on well-established prognostic factors. A number of features can predict the outcome of treatment including cytogenetics and an increasing list of molecular features. These are increasingly being used to direct postinduction therapy and support risk-adapted treatments that should achieve optimal results while minimizing nonrelapse mortality. In addition, they are also molecular targets for a new generation of small molecule inhibitors that are in early development and promise to further improve outcomes in the coming decade.
Keywords: acute myeloid leukemia, acute lymphoblastic leukemia, treatment, targeted therapy
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.